(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 October 2009 (01.10.2009)

PCT

(10) International Publication Number
WO 2009/118187 A1

(51) International Patent Classification:
A61K 31/505 (2006.01) *A61P 25/28* (2006.01)
C07D 403/06 (2006.01) *A61P 25/16* (2006.01)

(21) International Application Number:
PCT/EP2009/002241

(22) International Filing Date:
26 March 2009 (26.03.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/040,087 27 March 2008 (27.03.2008) US

(71) Applicant *(for all designated States except US)*: **EVOTEC NEUROSCIENCES GMBH** [DE/DE]; Schnackenburgallee 114, 22525 Hamburg (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KEMP, John, Alan** [GB/CH]; Amselstrasse 24, CH-4059 Basel (CH). **TASKER, Timothy** [GB/GB]; 12 Millside Place, Isleworth TW7 6BU (GB).

(74) Agent: **RUPP, Christian**; Mitscherlich & Partner, Postfach 33 06 09, 80066 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: METHODS FOR TREATING DISORDERS USING NMDA NR2B-SUBTYPE SELECTIVE ANTAGONIST

Subject	Plasma Sampling Time after dosing	CSF Sample taken x hours after dosing	CSF Concentration compound of formula (I) [ng/ml]	Plasma Concentration compound of formula (I) [ng/ml]	CSF/ plasma	Free drug plasma concentration compound of formula (I) [ng/ml]	CSF/ plasma free drug	CSF concentration of compound of formula (I) [nM]	receptor occupancy % (KD 20 nM)
1	3 hours	03:35	10.678	38.317	0.272	10.616	1.006	33.6	62.6525535
	4 hours	03:35	10.678	31.902	0.335	8.614	1.240	33.6	62.6525535
2	3 hours	03:15	14.986	73.337	0.204	19.801	0.757	47.1	70.1880925
	4 hours	03:15	14.986	58.137	0.258	15.697	0.955	47.1	70.1880925
3	3 hours	03:25	13.909	57.773	0.241	15.599	0.892	43.7	68.6044332
	4 hours	03:25	13.909	49.279	0.282	13.305	1.045	43.7	68.6044332
4	3 hours	03:15	12.137	46.059	0.263	12.976	0.935	38.1	65.5976046
	4 hours	03:15	12.137	38.131	0.318	10.295	1.179	38.1	65.5976046
5	3 hours	04:05	8.483	34.377	0.247	9.282	0.914	26.7	57.1315042
	4 hours	04:05	8.483	25.981	0.327	7.015	1.209	26.7	57.1315042
6	3 hours	03:15	8.51	43.168	0.197	11.661	0.730	26.7	57.2093148
	4 hours	03:15	8.51	30.149	0.282	8.14	1.045	26.7	57.2093148

FIG. 1



(I)

(57) **Abstract**: A method of treating, preventing or ameliorating a disease or condition by inhibiting NR2B subunit containing NMDA receptors using a compound according to formula (I) or a pharmaceutically acceptable salt thereof:

WO 2009/118187 A1